Data / Form D filings / Avivomed Inc.
Avivomed Inc.: Form D filings
Avivomed Inc., a biotechnology company in Roseville, MN, filed 2 Form D notices with the SEC between 2021 and 2026. The latest, on April 21, 2026, reports $5 million sold of a $12 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2896 Centre Pointe Drive, Roseville, MN, 55113
- Phone
- (612) 239-8104
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1893991
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 21, 2026 | New notice | $12,000,000 | $5,000,000 | $7,000,000 | 7 | Apr 16, 2026 | sec.gov |
| Nov 16, 2021 | New notice | $32,000,000 | $20,118,334 | $11,881,666 | 6 | Nov 3, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Paul Mazanec | Executive Officer, Director | |
| Mudit K. Jain | Director | |
| Ketan Patel | Director | |
| Theresa C. Pappas | Director | |
| Casper de Clercq | Director | |
| Douglas Reed | Director |
Other biotechnology companies in Minnesota that filed recently
- Medical 21, Inc. $550,000 · Oct 23, 2026
- InSitu Biologics, Inc. $1.3 million · Oct 14, 2026
- Evia Bio, Inc. $5.5 million · Sep 28, 2026
- EyeMacular Regeneration, Inc. $2.9 million · Sep 25, 2026
- ProEncia Biotechnology Inc. $1.5 million · Aug 26, 2026
Every Form D from the week of Apr 20, 2026 · All recent filings in Minnesota · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Avivomed Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.